Earlier this month, Google underwent a restructuring, creating a holding company named Alphabet, within which Google is but one component. We learned last week that one of the spines, perhaps the second most important one, of this umbrella will be life sciences. Google co-founder Sergey Brin announced on his blog on August 20 that "the life sciences team is now ready to graduate from our X lab and become a standalone Alphabet company, with Andy Conrad as CEO."
Andy Conrad, CEO of Alphabet's life sciences company.
Citing the glucose-sensing contact lens that Google developed and that was licensed to Novartis' Alcon eye-care division in July 2014, Brin writes: "While I am delighted at the progress that project has made, I could not have imagined the potential of the initiative it has grown into—a life sciences team with the mission to develop new technologies to make healthcare more proactive. The efforts it has spawned include a nanodiagnostics platform, a cardiac and activity monitor, and the Baseline Study."